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adding immense diversity to the function of the receptor in vivo. 
Furthermore, recent studies using animal models suggest that RNA 
editing of the 5-HT2C receptor is a dynamic process. For example, 
chronic stress increases the degree of RNA editing of the 5-HT2C 
receptor in both mice (Englander et al., 2005) and rats (Iwamoto 
et al., 2005). Variation in 5-HT2C receptor RNA editing has also 
been implicated in a variety of neuropsychiatric disorders, with 
the most reproducible ﬁ  nding being an increase in RNA editing in 
brains of suicide victims (Niswender et al., 2001; Gurevich et al., 
2002; Dracheva et al., 2008a,b). Despite these ﬁ  ndings, deﬁ  ning 
the in vivo functional consequences of 5-HT2C receptor RNA edit-
ing has been limited due to technical constraints presented by the 
immense diversity of receptor RNA isoforms in brain.
In vitro studies in cultured cells transfected with cDNA encod-
ing a single receptor isoform show that differentially edited 5-HT2C 
receptor isoforms have unique signaling features, with increased 
editing generally leading to decreased function. For example, the 
edited isoform valine-serine-valine (at amino acid positions 157, 
159, 161 in humans) has four-fold reduced constitutive activ-
ity and four- to ﬁ  ve-fold reduced serotonin potency to activate 
phospholipase C (PLC) relative to the non-edited isoleucine-
  asparagine-  isoleucine isoform (INI); the function of the fully 
edited valine-glycine-valine (VGV) isoform is reduced even further 
(Fitzgerald et al., 1999; Herrick-Davis et al., 1999; Niswender et al., 
INTRODUCTION
The serotonin 2C (5-HT2C) receptor modulates a number of neuro-
physiological functions including appetite, mood, sexual behavior, 
and locomotion (Buhot, 1997; Olivier et al., 1998; Giorgetti and 
Tecott, 2004; Millan, 2005), and is implicated in the etiology of 
psychiatric disorders such as depression, anxiety, anorexia-nervosa, 
and obsessive-compulsive disorder (Griebel, 1995; Delgado and 
Moreno, 1998; Berg et al., 2008; Flaisher-Grinberg et al., 2008). 
Consequently, the 5-HT2C receptor has received considerable atten-
tion as a target for pharmacological treatment of these conditions 
(Meltzer et al., 2003; Serretti et al., 2004; Millan, 2005; Halford et al., 
2007; Morabito and Emeson, 2009).
A distinctive feature of the G-protein coupled 5-HT2C receptor 
is its ability to be modiﬁ  ed posttranscriptionally by RNA editing 
(Burns et al., 1997). RNA editing is an enzymatic process that con-
verts adenosine to inosine at ﬁ  ve nucleotide positions in the 5th 
exon of the 5-HT2C receptor RNA transcript, encoding the second 
intracellular loop, a region important for G-protein coupling. 
Selective RNA editing can generate up to 32 mRNA isoforms, 
predicting 24 protein isoforms of the 5-HT2C receptor, potentially 
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studies examine the signal transduction properties of 5-HT2C-VGV receptors in brain to determine 
the in vivo consequences of altered editing. Using mice solely expressing the 5-HT2C-VGV receptor 
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of brain 5-HT2C-VGV receptors. However, enhanced behavioral sensitivity to a 5-HT2C receptor agonist 
was also seen in mice expressing 5-HT2C-VGV receptors, an unexpected ﬁ  nding given the blunted 
G-protein coupling. In addition, mice expressing 5-HT2C-VGV receptors had greater sensitivity to 
a 5-HT2C inverse agonist/antagonist enhancement of dopamine turnover relative to wild-type 
mice. These behavioral and biochemical results are most likely explained by increases in 5-HT2C 
receptor binding sites in the brains of mice solely expressing 5-HT2C-VGV receptors. We conclude 
that 5-HT2C-VGV receptor signaling in brain is blunted, but this deﬁ  ciency is masked by a marked 
increase in 5-HT2C receptor binding site density in mice solely expressing the VGV isoform. These 
ﬁ  ndings suggest that RNA editing may regulate the density of 5-HT2C receptor binding sites in 
brain. We further caution that the pattern of 5-HT2C receptor RNA isoforms may not reﬂ  ect the 
pattern of protein isoforms, and hence the inferred overall function of the receptor.
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signiﬁ  cantly different from the expected 50% (one sample t-test, 
t = 3.0949, df = 3, p > 0.05). The ﬁ  nding that the frequency of VGV 
isoform in the heterozygous VGV/X mice is about 50%, combined 
with subsequent results showing that receptor density in VGV/X 
mice is about halfway between WT and VGV/Y mice, suggests that 
there is not signiﬁ  cant bias in X-inactivation. We also veriﬁ  ed that 
the increase in the percentage of the VGV isoform in brains of 
VGV/X mice did not alter the remaining distribution of isoforms 
(Figure 1B).
DRUGS AND RADIOLIGANDS
MK212 hydrochloride [6-Chloro-2-(1-piperazinyl) pyrazine 
hydrochloride], purchased from Tocris Bioscience (Ellisville, MO, 
USA), was dissolved in deionized water, and injected subcutane-
ously (s.c.) at a volume of 10 ml/kg. [N6-methyl-3H]-Mesulergine 
([3H]-mesulergine) was purchased from GE Healthcare/
Amersham (Buckinghamshire, UK). (±)-1-(2,5,-dimethoxy-
4-[125I]iodophenyl)-2-aminopropane ([125I]-DOI) was purchased 
from Perkin Elmer (Boston, MA, USA). Spiperone and methy-
sergide were purchased from Sigma-Aldrich (St. Louis, MO, USA); 
SB206553 was purchased from Tocris Bioscience.
GTP-SENSITIVE HIGH-AFFINITY AGONIST BINDING IN MEMBRANES
Agonists, such as DOI, bind preferentially to 5-HT2C receptors exist-
ing in a high-afﬁ  nity state, a receptor conformation that is coupled 
to G-protein. In vitro, 5-HT2C-VGV receptors show no basal coupling 
to G-proteins (Herrick-Davis et al., 1999; Niswender et al., 1999). 
We tested whether this recapitulates in brain. Mice were brieﬂ  y 
anesthetized using isoﬂ  urane and decapitated. Unless otherwise 
indicated, brains were removed, placed in a slicing mold, and sliced 
coronally at the level of the optic chiasm. Tissue anterior to the cut, 
deﬁ  ned here as forebrain, was assayed. Tissue was homogenized in 
20 ml of ice cold binding buffer (50 mM Tris, 10 mM MgCl2, 0.1% 
ascorbic acid, pH 7.4). Homogenates were centrifuged at 15,000 × g 
for 20 min. at 4°C. Supernatant was decanted, and the pellet was 
re-suspended in fresh binding buffer and incubated at 37°C for 
15 min to dissociate endogenous ligand from receptors. After a 
second centrifugation, supernatant was decanted, and the pellet 
re-suspended in fresh, cold binding buffer. Binding assays were run 
on the same day as the membrane preparation to avoid a decrease 
in signal due to freezing.
[125I]-DOI saturation binding was performed on membranes 
from VGV/Y and WT mice to test potential differences in the pro-
portion of receptors in the agonist high-afﬁ  nity conformation. 
Assays were carried out in triplicate and incubated for 90 min in 
a 37°C water bath at ﬁ  nal volume of 600 µl, consisting of 500 µl 
of membrane suspension, 1 µM spiperone to mask 5-HT2A and 
5-HT7 binding sites and increasing concentrations of [125I]-DOI. 
Non-speciﬁ  c binding was determined in the presence of 100 µM 
methysergide. Data were analyzed using nonlinear regression 
(GraphPad Prism 5.02, Graphpad Inc., USA). In a separate experi-
ment, GTP sensitivity was evaluated using a single concentration of 
[125I]-DOI (1 nM) in the absence and presence of 200 µM guanylyl-
5′-  imidodiphosphate (Gpp(NH)p), a non-hydrolyzable analog of 
GTP that prevents G-protein coupling. Total density was estimated 
in each membrane preparation using a single saturating concentra-
tion (30 nM) of [3H]-mesulergine.
1999). These studies suggest dramatic alterations will accompany 
changes in RNA editing of the 5-HT2C receptor; however, it is widely 
accepted that functional properties demonstrated in cell culture 
studies of cloned receptors may not be reproduced in vivo.
Since the majority of 5-HT2C receptors in brain are edited (Burns 
et al., 1997), studies of the in vivo functional consequences of 5-
HT2C receptor RNA editing are critically needed. Here we take 
advantage of mutant mice solely expressing a single isoform, the 
fully-edited 5-HT2C-VGV receptor, to characterize for the ﬁ  rst time 
the signal transduction consequences of RNA editing of the 5-HT2C 
receptor in vivo. We show that the proximal event in cell signaling, 
receptor:G-protein coupling, is nearly abolished for the fully edited 
5-HT2C-VGV receptor in brain. We further show that changes in the 
degree of editing signiﬁ  cantly alters the density of receptor bind-
ing sites within the brain, suggesting that the pattern of protein 
isoforms, and hence the inferred overall function of the receptor 
protein, may not reﬂ  ect the pattern of RNA isoforms. This ﬁ  nding 
has signiﬁ  cant ramiﬁ  cations for basic as well as clinical studies of 
disease-related alterations in RNA editing of the 5-HT2C receptor.
MATERIALS AND METHODS
ANIMALS
All experiments involving animals were approved by the Institutional 
Animal Care and Use Committee of Vanderbilt University. Naive 
adult mice, 3–6 months of age, were used for all experiments. Mice 
were housed in groups of 2–5 in a temperature controlled, colony 
room (ambient temperature 22–23°C, 12:12 light: dark cycle). 
Food and water were available ad libitum, and all testing occurred 
between 1200 and 1700 during the light phase. Unless otherwise 
indicated, male mice were used.
Mutant mice solely expressing 5-HT2C-VGV receptors were gener-
ated by homologous recombination using a replacement-type tar-
geting vector with the ﬁ  ve edited adenosine residues of the 5-HT2C 
receptor gene mutated to guanosine to mimic the base-  pairing 
properties of inosine (Morabito et al., 2007). Mice were maintained 
on a mixed JAX® 129S1/Taconic® 129S6 background. Four geno-
types of mice were used in the experiments   examining functional 
characteristics of the in vivo expressed 5-HT2C-VGV receptor: wild-
type males and females (WT), heterozygous females (VGV/X), and 
hemizygous (the 5-HT2C receptor is X-linked) males (VGV/Y), 
expressing solely the VGV isoform. The genotypes of mice were 
determined by PCR analysis of genomic DNA from tail samples 
using the RED Extract-N-Amp tissue PCR kit (Sigma, St. Louis, 
MO, USA), with the following primers: 5′GGG CAA ATA TTC 
TGA AAA GAT GTT 3′ (reverse) and 5′AAT ATC AAT AGG TAA 
TTA TAC C 3′ (forward).
To assess the possible contribution of gene dosing, heterozygous 
mice expressing a mixture of receptor isoforms enriched with the 
mutant allele were used; these studies were performed in female 
mice since the 5-HT2C receptor is X-linked and it is not possible to 
generate heterozygote males. Using the method of pyrosequencing 
(Canal et al., 2009), we veriﬁ  ed that heterozygous VGV/X females 
had VGV as the major isoform,while control mice (N = 4, average 
of 60 sequences per mouse) had less than 1% VGV isoforms. VGV/X 
females (N = 4, average of 60 sequences per mouse) had an aver-
age of 62% of RNA isoforms that translate to VGV (Figure 1A); 
although suggestive of biased X-inactivation, this value was not 
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Samples were incubated for 90 min in a 37°C water bath, 
and the reactions were terminated by the addition of ice-cold 
50 mM Tris buffer. Membranes were collected by vacuum ﬁ  ltra-
tion (Brandel harvester) using Whatman GF/B glass ﬁ  ber ﬁ  lters 
presoaked in 0.3% polyethyleneimine. Filters were rinsed three 
times with cold Tris buffer, and the bound radioactivity was 
determined by liquid scintillation spectrometry after soaking ﬁ  l-
ters overnight in scintillation cocktail (Aquasol-2, PerkinElmer, 
Boston, MA, USA).
[125I]-DOI AND [3H]-MESULERGINE AUTORADIOGRAPHY
Mice were anesthetized with isoﬂ  urane inhalation, followed by 
decapitation. Brains were quickly removed and frozen in 2-meth-
ylbutane on dry ice, dried brieﬂ  y with a Kimwipe (Kimberly-
Clark, Roswell, GA, USA), wrapped in aluminum foil and stored 
at −80°C. Brains were brought to −20°C in a cryostat (Leica, Wetzlar, 
Germany), sectioned at 20 µm and thaw mounted onto Superfrost 
glass slides (Fisher, USA), then stored at −80°C until the autora-
diographic assay.
For [125I]-DOI autoradiography, slides were thawed at room tem-
perature for 30 min, followed by incubation for 30 min in assay 
buffer containing 50 mM Tris, 5 mM MgSO4, 4 mM CaCl2 and 
0.5 mM EDTA. Slides were then transferred to assay buffer that 
contained one of four drug treatments: (1) 0.14 nM [125I]-DOI to 
label 5-HT2A and 5-HT2C receptors; (2) 0.14 nM [125I]-DOI plus 
100 nM spiperone to identify the 5-HT2C receptor; (3) 0.14 nM 
[125I]-DOI plus 100 µM GTPγS to identify GTP-sensitive high afﬁ  n-
ity [125I]-DOI binding (Appel et al., 1990); (4) 0.14 nM [125I]-DOI 
plus 30 µM methysergide to deﬁ  ne non-speciﬁ  c binding. Slides 
were incubated with radioligand at room temperature for 60 min, 
then washed 4 × 10 min in ice-cold 50 mM Tris buffer, pH 7.4 and 
dried with a steady stream of dehumidiﬁ  ed air.
[3H]-mesulergine autoradiography procedures were identical 
to [125I]-DOI autoradiography with the following exceptions. The 
assay buffer for [3H]-mesulergine was 50 mM Tris, 10 mM MgCl2, 
and 0.1 mM EDTA. The binding conditions were: (1) 3 nM [3H]-
mesulergine; (2) 3 nM [3H]-mesulergine plus 100 nM spiperone; 
(3) 3 nM [3H]-mesulergine plus 30 µM methysergide to deﬁ  ne 
FIGURE 1 | Distribution of 5-HT2C RNA isoforms. (A) Percentage distribution 
of Htr2c RNA editing in cortex of wild type (WT, Ο) control female mice and 
heterozygous VGV/X (X) transgenic mice, for editing sites (top), observed RNA 
sequences (middle), and predicted receptor protein isoforms (bottom). 
Differences in other proportions (e.g., ABD, VNV) reﬂ  ect inclusion of VGV in the 
calculation of the editing measures (%). Heterozygous VGV/X females 
expressed the 5-HT2C-VGV isoform at a quantity (mean = 61.9%, 95% 
CI 49.7–74.1%) that was signiﬁ  cantly higher than the rare expression observed 
in wild type litter mate females (two sample t-test, t = 15.89, df = 6, p < 0.0001) 
and signiﬁ  cantly lower than the 100% expression seen in VGV homozygous 
females and hemizygous VGV/Y males (one sample t-test, t = −9.92, df = 3, 
p = 0.002). (B) Percentage distribution of Htr2c RNA excluding the fully edited 
sequences (ABECD or VGV) shows that the remaining distribution is unaltered 
by the presence of a VGV transgenc (Fischer’s exact Chi-square test p = 0.37).
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non-speciﬁ  c binding. The addition of 300 nM SB204741, a 5-HT2B 
antagonist, did not alter [3H]-mesulergine binding in WT or VGV/Y 
brain slices.
Slides were incubated for 120 min at room temperature, then 
washed 4 × 10 min in ice-cold 50 mM Tris buffer, pH 7.4 and dried 
with a steady stream of dehumidiﬁ  ed air.
After air drying for an additional 90 min, slides were placed 
in autoradiography cassettes and exposed to Kodak Biomax MR 
ﬁ  lm (Carestream Health, Inc., USA) for 24–48 h for [125I]-DOI 
or 6–8  weeks for 3H-mesulergine prior to developing (shorter 
exposures were required for brain sections from VGV/Y mice to 
accommodate an increased density of 5-HT2C receptors). Film was 
scanned (CanoScan 4400F, Canon, USA) onto a PC, and images 
were analyzed with Image J software (Abramoff et al., 2004). The 
average of the minimum gray value (darkest area) from three brain 
slices containing brain area of interest was converted to µCi/g pro-
tein using 14C standards (ARC, Inc., St. Louis, MO) for statistical 
comparisons of speciﬁ  c [125I]-DOI binding, and 3H standards for 
statistical comparisons of speciﬁ  c [3H]-mesulergine. Data were 
compared using 2-tailed unpaired t-tests.
5-HT2C RECEPTOR AGONIST IMPACT ON LOCOMOTOR ACTIVITY IN VGV/Y 
AND VGV/X
Dose-response studies were conducted to assess the locomotor 
effects of MK212, a preferential 5-HT2C receptor agonist (Fone 
et al., 1998; Gleason et al., 2001; Stiedl et al., 2007; Fletcher et al., 
2009) in WT, hemizygous VGV/Y and heterozygous VGV/X mice. 
Locomotor activity was measured in Plexiglas activity chambers 
(11 × 11 × 11 in; LxWxH; Med Associates St. Albans, Vermont), 
equipped with 16 infrared beams to monitor and record beam 
breaks in the x–y–z coordinates. VGV/Y and VGV/X mice were 
tested with saline and MK212 at doses of 0.01, 0.03, 0.1, 0.3 and 
1.0 mg/kg. Twenty minutes after s.c. injection, individual mice 
were placed inside the activity chamber and distance traveled was 
recorded for 10 min using Activity Monitor software version 5 (Med 
Associates, St. Albans, Vermont, USA). Dose-response data were 
analyzed by two-way ANOVA for independent groups.
BIOGENIC AMINE TURNOVER IN VGV/Y MICE
Dopamine (DA), serotonin (5-HT) and metabolites were quanti-
ﬁ  ed by high-performance liquid chromatography (HPLC) electro-
chemical detection methods (Vanderbilt Neurochemistry Core). 
Animals were anesthetized with isoﬂ  urane and rapidly decapitated 
after cervical dislocation. Brains were removed and placed in a 
chilled stainless steel mold for dissection – the tissue slice 1.7–3.6 
relative to bregma is referred to as frontal cortex; striatum repre-
sents slice 1.70 to −0.82 relative to bregma with the cortex removed 
by freehand dissection. Tissue was frozen rapidly on dry ice and 
stored at −80°C until assay. Thawed samples were homogenized in 
250 µl acetonitrile and centrifuged at 13,000 × g for 30 min. The 
acetonitrile fraction was transferred to a clean tube, washed twice 
with 125 µl heptane and then evaporated using a stream of nitro-
gen. The sample was suspended in 75 µl of the HPLC mobile phase 
(37.5 mmol H3PO4, pH 8.5) and 50 µl was injected into the equili-
brated HPLC. DA turnover was measured by the ratio DOPAC/DA 
and HVA/DA; 5-HT turnover was measured by the ratio 5-HIAA/
5-HT. Each measure was predicted by a mixed ANOVA model that 
incorporated between-subject ﬁ  xed effects for genotype (VGV/Y or 
WT) and drug (saline or SB206553), a within-subject ﬁ  xed effect 
for brain area (frontal cortex or striatum), and a random effect to 
account for repeated measures in each mouse.
[3H]-MESULERGINE SATURATION BINDING IN MEMBRANES
The procedures for [3H]-mesulergine saturation binding were 
essentially identical to [125I]-DOI binding in membranes. Membrane 
homogenates, binding buffer, spiperone at a ﬁ  nal concentration of 
1 µM, and increasing concentrations of [3H]-mesulergine up to 
36 nM were added. Non-speciﬁ  c binding was determined in the 
presence of 100 µM methysergide.
RESULTS
5-HT2C-VGV RECEPTORS IN BRAIN EXHIBIT REDUCED HIGH-AFFINITY 
AGONIST BINDING: MEMBRANE BINDING
In saturation binding assays of membranes from WT littermates, 
the binding of the radiolabeled agonist [125I]-DOI was best ﬁ  t by a 
two-site equation, as illustrated in the Scatchard plot (Figure 2A). 
Approximately 10% of the binding sites were in a high afﬁ  nity 
state (Kd = 0.51 nM).The low-afﬁ  nity site had a Kd (20 nM) and 
density of 137 fmol/mg protein. In contrast, [125I]-DOI binding in 
membranes from VGV/Y mice was best ﬁ  t by a one-site equation, 
as illustrated in the Scatchard plot (Figure 2B) with a Kd (29 nM) 
that was consistent with the Kd of the low afﬁ  nity site in WT mice. 
The extremely high density of binding sites in VGV/Y mice was 
conﬁ  rmed in [3H]-mesulergine binding experiments (see below).
To corroborate the ﬁ  nding of decreased high-afﬁ  nity binding 
sites in brains of VGV/Y mice and to estimate the percentage of 
G-protein coupled receptors, the binding of a single concentra-
tion of [125I]-DOI was determined in the absence and presence 
of Gpp(NH)p to uncouple the receptor:G-protein complex 
(Figure 3). Fifty-seven percent of the [125I]-DOI binding in mem-
branes from WT mice was eliminated by addition of Gpp(NH)p; 
in contrast [125I]-DOI binding in membranes from VGV/Y mice 
was Gpp(NH)p-insensitive (Figure 3).
5-HT2C-VGV RECEPTORS IN VIVO EXHIBIT REDUCED GTP-SENSITIVE HIGH 
AFFINITY AGONIST BINDING: [125I]-DOI AUTORADIOGRAPHY
[125I]-DOI binding to 5-HT2C receptors was clearly visible in the 
choroid plexus in brain slices from WT and VGV/Y mice; thus 
the choroid plexus was used for analysis of GTP sensitivity of 5-
HT2C receptor binding. As illustrated in Figure 4, the addition of 
GTPγS to WT sections incubated with [125I]-DOI decreased speciﬁ  c 
binding in choroid plexus (45.7 ± 6.52% decrease; N = 5; p < 0.05). 
However, GTPγS did not signiﬁ  cantly alter [125I]-DOI binding in 
choroid plexus of VGV/Y sections (5.5 ± 3.9% decrease; N = 6; 
p = 0.15), conﬁ  rming greatly reduced high-afﬁ  nity, GTP-sensitive, 
agonist binding at 5-HT2C-VGV receptors.
VGV/Y MICE HAVE INCREASED SENSITIVITY TO 5-HT2C RECEPTOR 
AGONIST: LOCOMOTOR ACTIVITY
Injection of the 5-HT2C agonist, MK212, dose-dependently 
decreased total distance traveled in all genotypes, yet the potency 
of MK212 was greater in mutant mice relative to their respective WT 
littermates. For WT, female VGV/X and VGV/Y mice (Figure 5), 
a 2-way ANOVA revealed main effects of dose (F5,135 = 31.77, 
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FIGURE 2 | Agonist high afﬁ  nity binding: Membranes from WT and VGV/Y 
mice. Representative saturation plots of speciﬁ  c [125I]-DOI binding are shown for 
membranes from WT (A), and VGV/Y mice (B). Increasing concentrations of 
[125I]-DOI are plotted on the x-axis and density (fmol/mg protein) is plotted on the 
y-axis. Data were tested for best ﬁ  t to one- or two-site models (GraphPad Prism 
5.02). Insets show Scatchard transformation of the saturation binding data, 
bound/free (y-axis) versus bound (x-axis). Scatchard plots illustrate the absence 
of high-afﬁ  nity agonist binding sites in VGV/Y mice.
FIGURE 3 | GTP sensitive agonist binding: Membranes from WT and 
VGV/Y. Gpp(NH)p (200 µM) was added to assay buffer containing 1 nM 
[125I]-DOI to eliminate high afﬁ  nity binding; the [125I]-DOI binding in the absence 
and presence of Gpp(NH)p is plotted. Membranes from VGV/Y show no 
detectable GTP-sensitive [125I]-DOI binding to 5-HT2C receptors. A signiﬁ  cant 
effect of genotype was observed (F1,43 = 54.66, p < 0.0001).
FIGURE 4 | Agonist high afﬁ  nity binding: autoradiography of brain slices from WT and VGV/Y mice. Representative [125I]-DOI autoradiography. (A) WT sections 
incubated in 0.14 nM [125I]-DOI plus 1 μM spiperone. (B) VGV/Y sections incubated in 0.14 nM [125I]-DOI plus 1 μM spiperone. (C) WT sections incubated in 0.14 nM 
[125I]-DOI plus 100 μM GTPγS. (D) VGV/Y sections incubated in 0.14 nM [125I]-DOI plus 100 μM GTPγS. The addition of GTPγS reduced binding in choroid plexus of 
sections from WT, but not VGV/Y mice.
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p < 0.0001) and genotype (F2,135 = 42.46, p < 0.0001). The potency 
of MK212 was 10-fold higher in VGV/Y and VGV/X mice rela-
tive to WT’s (Figure 5; N = 10). For example, 0.1 mg/kg MK212 
essentially eliminated locomotor activity in VGV/Y mice (post-hoc 
Fisher least signiﬁ  cant difference (LSD) test, saline vs. 0.1 mg/kg, 
p < 0.001), whereas this dose did not reduce locomotor activity in 
WT mice (post-hoc Fisher LSD test, saline vs. 0.1 mg/kg, p = 0.58). 
There were no gender differences in the motor effects of MK212 
in WT mice (data not shown).
VGV/Y MICE HAVE INCREASED SENSITIVITY TO 5-HT2C RECEPTOR 
INVERSE AGONIST: DA TURNOVER
Given that the 5-HT2C receptor has been reported to exert an 
inhibitory inﬂ  uence on DA release, we asked if the DA turnover 
is decreased in VGV/Y mice and further if SB206553 differentially 
altered DA turnover. Twenty minutes after treatment with saline or 
3 mg/kg of the inverse agonist SB206553, biogenic amine levels were 
determined in striatum and cortex of VGV/Y and WT male mice 
(Table 1). DA turnover was measured by the ratio DOPAC/DA and 
the ratio HVA/DA, and 5-HT turnover was measured by the ratio 
5-HIAA/5-HT. Each measure was predicted by a mixed ANOVA 
model that incorporated between-subject ﬁ  xed effects for genotype 
(VGV/Y or WT) and drug (saline or SB206553), a within-subject 
ﬁ  xed effect for brain area (cortex or striatum), and a random effect 
to account for repeated measures in each mouse.
Although basal DA turnover (saline treated) was reduced in 
cortex of VGV/Y mice (p = 0.039 for DOPAC/DA, p = 0.063 for 
HVA/DA, least-squared difference post-hoc tests, Figures 6A,B), this 
effect was small and not reproduced in the striatum. A more striking 
dopamine phenotype occurred in both cortex and striatum follow-
ing SB206553 challenge. Signiﬁ  cant genotype by drug interactions 
were observed for the ratios DOPAC/DA (Figure 6A), HVA/DA 
(Figure 6B), and for 5-HIAA/5-HT (Figure 6C). Similar interac-
tion proﬁ  les of the marginal means were observed for each turno-
ver measure (Figure 6), where VGV/Y mice showed   signiﬁ  cantly 
increased turnover after SB206553 challenge compared to saline, 
but WT mice revealed a relatively ﬂ  atter proﬁ  le across saline and 
SB206553 conditions.
VGV/Y MICE SHOW LARGE INCREASES IN 5-HT2C RECEPTOR DENSITY: 
[3H]-MESULERGINE SATURATION BINDING
[3H]-Mesulergine saturation binding was performed to determine 
the maximum density of 5-HT2C receptor binding sites in brains 
of WT, VGV/Y and VGV/X mice (Figure 7). All plots were best ﬁ  t 
by a single site equation. The density of 5-HT2C receptors in the 
forebrain was increased by 25-fold in VGV/Y mice relative to WT 
mice (Bmax = 163.3 ± 5.9 fmol/mg protein in WT vs. 4266 ± 260 in 
VGV/Y; N = 4). Heterozygous VGV/X mice displayed an approxi-
mately 10-fold increase in the density of [3H]-mesulergine bind-
ing sites (Bmax = 1754 ± 149 fmol/mg protein; N = 8), which was 
intermediate to that observed for WT and VGV/Y mice. The Kd 
values for [3H]-mesulergine were identical in all three genotypes. 
Furthermore, in competition binding experiments, the Ki values 
for MK212, SB206553 and spiperone were not altered in mem-
branes from VGV/Y vs WT mice (data not shown).
VGV/Y MICE SHOW LARGE INCREASES IN 5-HT2C RECEPTOR DENSITY: 
[3H]-MESULERGINE AUTORADIOGRAPHY
Similar to results of saturation binding experiments, [3H]-
  mesulergine autoradiograms showed tremendous increases in 
5-HT2C receptor density in VGV/Y mice (Figure 8). WT speciﬁ  c 
binding versus VGV/Y speciﬁ  c binding was signiﬁ  cantly increased 
(p < 0.05) in all regions examined [e.g., 89% increase in nucleus 
accumbens of VGV/Y mice (N = 6) relative to WT (N = 5)]. The 
FIGURE 5 | MK212 dose-dependent induction of hypolocomotion. 
Locomotor activity of WT, VGV/X, and VGV/Y mice after single subcutaneous 
injection of saline or MK2I2 (0.01, 0.03, 0.1, 0.3 or 1.0 mg/kg). *Denotes 
signiﬁ  cantly different from saline within group. #Denotes signiﬁ  cantly 
different from WT.
Table 1 | Biogenic amines.
Amine/metabolite DOPAC  Dopamine  5-HIAA  5-HT  HVA
Genotype  WT  VGV WT  VGV  WT  VGV  WT  VGV WT VGV
FRONTAL CORTEX
Saline 7 .1  ± 1.8  10.2 ± 1.8  31.5 ± 10.4  68.2 ± 11.4*  10.4 ± 0.88  13.6 ± 1.7  25.9 ± 1.2  30.8 ± 2.2  6.7 ± 1.6  11.2 ± 1.8
SB206553 6.6  ± 0.8  15.6 ± 1.7  28.9 ± 6.7  34.2 ± 6.3  9.1 ± 0.7  16.0 ± 0.8  24.5 ± 2.4  20.0 ± 0.9  6.0 ± 0.7  13.9 ± 1.3
STRIATUM
Saline 15.3  ± 1.3  11.8 ± 0.9  111.9 ± 5.6  116.6 ± 7 .5  19.4 ± 3.1  16.9 ± 1.8  26.6 ± 1.6  24.8 ± 1.4  17 .1 ± 1.2  27 .5 ± 1.5
SB206553 14.39  ± 1.4  24.1 ± 1.0  110.8 ± 10.7  95.0 ± 15.1  18.9 ± 0.7  26.2 ± 1.1  25.9 ± 1.8  25.4 ± 0.6  16.2 ± 1.3  16.1 ± 1.1
The results are presented as means ± SEM (n = 5). *Signiﬁ  cantly different from WT, p < 0.01. Data were analyzed with ANOVAs.
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widespread increase in 5-HT2C receptor binding in thalamus, 
amygdala, posterior cingulate cortex, piriform cortex (Figure 8) 
appears to reproduce the distribution in WT mice, suggesting that 
overexpression in the mutant mice does not reﬂ  ect an aberrant 
distribution of the 5-HT2C receptor.
DISCUSSION
5-HT2C receptor RNA transcripts undergo ﬁ  ve adenosine to ino-
sine RNA editing events, resulting in the generation of distinct 
amino acids in the second intracellular loop of the protein, a region 
critical for G-protein coupling (Moro et al., 1993; Ballesteros et al., 
1998; Gaborik et al., 2003). Combinations of the ﬁ  ve edited nucle-
otides predict 24 different protein isoforms (Burns et al., 1997); 
many isoforms display altered signaling properties in transfection 
experiments in cell lines. The fully-edited VGV isoform, where all 
ﬁ  ve sites are edited, shows the most dramatic decrease in agonist 
potency, as well as silencing of receptor constitutive activity and 
elimination of high-afﬁ  nity, Gpp(NH)p sensitive agonist bind-
ing (Niswender et al., 1999). The current set of experiments takes 
advantage of genetically modiﬁ  ed mice solely expressing the VGV 
isoform to show, for the ﬁ  rst time in brain, that RNA editing of the 
5-HT2C receptor alters the proximal event in cell signaling, receptor:
G-protein coupling.
Several techniques were used to highlight the in vivo properties 
of the 5-HT2C-VGV receptor including [3H]-mesulergine saturation 
binding, [3H]-mesulergine autoradiography, [125I]-DOI satura-
tion binding, and [125I]-DOI GTP-sensitive high afﬁ  nity binding 
in membranes and in autoradiography. Nonlinear regression analy-
sis of [125I]-DOI saturation binding revealed two saturable binding 
sites in membranes from brains of WT mice, with the high afﬁ  n-
ity site representing nearly 10% of the total binding. In contrast, 
nonlinear regression analysis of [125I]-DOI saturation binding to 
membranes from mice expressing the VGV isoform reveals only a 
single, low-afﬁ  nity site, even though receptor density is increased 
dramatically. Based on the extended ternary complex model of 
receptor:G-protein coupling (Samama et al., 1993), it is likely that 
the loss of high afﬁ  nity binding reﬂ  ects reduced G-protein coupling. 
FIGURE 7 | 5-HT2C receptor density in WT, VGV/X, and VGV/Y mice. 
Mesulergine saturation binding analyses are shown for VGV/Y and VGV/X mice 
(A), and WT mice (B), The data are means of triplicate determinations and 
represent four to eight separate experiments. Mean values were as follows. 
Bmax (fmol/mg protein) ± SEM: VGV/ Y, 4266 ± 259.9 **(p < 0.001 compared to 
WT and VGV/ X); VGV/X, I754 ± 149 *(p < 0.001 compared to WT); WT, 
163.3 ± 5.9. Kd (nM) ± SEM: VGV/Y. 3.18 ± 0.23; VGV/X, 2.49 ± 0.30; WT, 
2.13 ± 0.26. Differences between means were determined by a one-way 
ANOVA followed by a Tukey test.
FIGURE 6 | SB206553 increases DA and 5-HT turnover in VGV/Y mice. (A) 
DA turnover (DOPAC/DA) following administration of saline or SB206553 
(3 mg/kg) in WT (S) and VGV/Y (•) mice; cortex (left), striatum (right). (B) HVA/
DA and (C) 5-HT turnover (5-HIAA/5-HT) after the same conditions. Signiﬁ  cant 
genotype by drug interactions were observed for the ratio DOPAC/DA 
(F1,16 = 20.39, p = 0.0004), for HVA/DA (F1,16 = 8.10, p = 0.0117) and for 
5-HlAA/5-HT (Fl,16 = 19.42, p = 0.0004).
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total  3H-mesulergine binding is increased, the proportion of 
GTP- sensitive  high  afﬁ  nity [125I]-DOI binding is reduced nearly 
eight-fold in choroid plexus of VGV/Y mice. These experiments 
conﬁ  rm that the blunted G-protein coupling of the VGV isoform 
described in cell lines is reproduced in a native setting. We conclude 
therefore that it is valid to interpret in vivo increases in the degree 
of RNA editing of the 5-HT2C receptor as a loss of function at the 
cellular level. An attempt to evaluate the classical effector path-
way, Gq   mediated-PLC activation, was unsuccessful; 5-HT failed 
to elicit a PLC signal in cortical tissue from wild-type or VGV/Y 
mice. Previous studies of 5-HT2C receptor-mediated PLC activation 
in rat brain were performed in choroid plexus (Conn and Sanders-
Bush, 1986), but this was not feasible in mice.
Our studies also suggest that changes in the proportion of edited 
isoforms alter the density of 5-HT2C receptor binding sites within 
the brain. VGV/Y mice, solely expressing the VGV isoform, have a 
25-fold increase in 5-HT2C receptor density relative to WT mice, 
similar to that found by Morabito et al. (2007). In heterozygous 
VGV/X mice, the percentage of RNA isoform encoding VGV and the 
density of 5-HT2C receptor binding sites is approximately halfway 
between WT and VGV/Y mice. This gene-dose dependent increase 
in binding site density supports the notion that the increases are not 
the result of erroneous genetic manipulation. In addition, receptor 
autoradiography suggests that the increased expression of 5-HT2C 
To test this further, [125I]-DOI binding was carried out in the pres-
ence and absence of a GTP analog. The addition of Gpp(NH)p 
reduces the binding of [125I]-DOI in brain membranes from WT 
mice, but has essentially no effect on [125I]-DOI binding in mem-
branes from VGV/Y mice, suggesting that the G-protein coupling 
capacity is compromised in brains of mice solely expressing the 5-
HT2C-VGV receptors. An unexpected ﬁ  nding was the marked increase 
in total [125I]-DOI binding in brains of VGV/Y mice relative to WT, 
with a binding site density comparable to that found in the choroid 
plexus (Conn and Sanders-Bush, 1986). We considered the pos-
sibility that Gq/11 protein may become rate-limiting in the case 
of the large increase in receptor density in brains of VGV/Y mice. 
However, quantitative studies of Milligan (1993) show that the 
level of Gq protein in rat frontal cortex is 17 pmol/mg protein and 
combined Gq/G11, 25 pmol/mg protein, which is ﬁ  ve-fold higher 
than receptor density in VGV/Y mice. Furthermore, we have previ-
ously shown that the levels of Gq and G11 protein are not altered 
in VGV/Y mice (Canal et al., 2009). These ﬁ  ndings suggest that 
Gq/11protein is not rate limiting in the brains of VGV/Y and that 
the reduction in GTP-sensitivity reﬂ  ects reduced coupling capacity 
of the VGV isoform.
Consistent with a reduction in G-protein coupling capacity 
found in membranes prepared from brains of VGV/Y mice, recep-
tor autoradiography in intact brain slices reveals that, although 
FIGURE 8 | 5-HT2C receptor density and distribution: [3H]-mesulergine 
autoradiography in brain slices. (A) Representative [3H]-mesulergine 
autoradiography of brain sections from WT and VGV/Y mice. (a) Sections 
incubated in 3 nM [3H]-mesulergine: (b) plus 1 µM spiperone: (c) plus 30 µM 
methysergide. (B) Representative [3H]-mesulergine autoradiographs of brain 
sections displaying 5-H2C receptors in WT, and VGV/Y mice. Increases 
in 5-HT2C-receptor expression in VGV/Y mice are observed in several 
brain structures. Abbreviations; CP , choroid plexus; PV, paraventricular
 thalamic nucleus; Pir, piriform cortex; Am, amygdala; PCC, posterior 
cingulate cortex.
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2004; Navailles et al., 2004; Alex and Pehek, 2007), we examined 
DA turnover as another index of in vivo 5-HT2C receptor function. 
5-HT2C receptor regulation of DA release is complex, involving 
direct and indirect pathways; microdialysis studies suggest that the 
mechanism of regulation differs in the nigrostriatal versus mesocor-
ticolimbic DA systems (Di Matteo et al., 1999; Di Giovanni et al., 
2000; see Di Matteo et al., 2008 for review). This may explain the 
regional difference seen in saline-treated VGV/Y mice, where DA 
turnover in the mutant mice is decreased in frontal cortex but not in 
striatum. Microdialysis experiments combined with direct micro-
injection would be valuable in pursuing this question. The ﬁ  nding 
that SB206553 increases DA turnover in frontal cortex and striatum 
of VGV/Y mice is consistent with the evidence that 5-HT2C receptors 
inhibit DA release in both areas. The ability of SB206553 to increase 
DA release has been proposed to reﬂ  ect constitutive activity of the 
5-HT2C receptor (De Deurwaerdere et al., 2004); however, such an 
explanation is less plausible in mice solely expressing the VGV iso-
form, since in vitro data in transfected cells shows that this isoform 
is essentially devoid of constitutive activity (Herrick-Davis et al., 
1999; Niswender et al., 1999; Wang et al., 2000; Berg et al., 2008) and 
the present studies in brain are consistent with that interpretation. 
An alternative explanation is suggested by our ﬁ  nding of increased 
5-HT turnover in VGV/Y mice given SB206553; enhanced release 
of 5-HT onto the up-regulated 5-HT2C receptors may play a role in 
the SB206553 modulation of DA release in VGV/Y mice.
In summary, in vitro studies in transfected cell lines have shown 
that RNA editing of 5-HT2C receptor RNA transcripts profoundly 
alters the signaling properties of the 5-HT2C receptor protein. The 
current studies utilizing genetically modiﬁ  ed mice solely expressing 
the most extensively edited isoform of the 5-HT2C receptor show, for 
the ﬁ  rst time, that the G-protein coupling capacity in the brain is 
altered, i.e., expression of fully edited 5-HT2C-VGV receptor isoform 
within the brain blunts receptor:G-protein coupling. We further show 
that changes in the degree of editing signiﬁ  cantly alters the density of 
receptor binding sites within the brain, suggesting that the pattern 
of protein isoforms, and hence the inferred overall function of the 
receptor protein, may not reﬂ  ect the pattern of RNA isoforms. This 
conclusion points to a critical need for a method that differentiates 
5-HT2C receptor protein isoforms in brain tissue. Until such a method 
becomes available, clinical and laboratory investigations must con-
tinue to rely on RNA isoform distribution to infer function. Our 
studies emphasize the need for caution in these interpretations.
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receptor in VGV/Y mice does not reﬂ  ect aberrant distribution of 
the receptor. It is possible that the increased density is a compensa-
tory response to reduced cellular function of the edited receptor. 
In support of this conclusion, transgenic mice solely expressing 
the non-edited, highly functional, 5-HT2C-INI receptor have reduced 
receptor density (unpublished results).
The molecular mechanism of the substantial density alteration 
in mutant mice is unknown. In the initial characterization of the 
VGV/Y mouse phenotype, Morabito et al. (2007) found no change 
in the steady state levels of 5-HT2C receptor RNA transcripts was 
detected. Other possible mechanisms include differences in transla-
tion efﬁ  ciency or stability of different protein isoforms. The latter is 
suggested by studies in cultured cells showing that the VGV isoform 
has diminished ability to bind to beta-arrestin and translocate into 
intracellular compartments (Marion et al., 2004). It is important to 
point out that the RNA isoform distribution, even in heterozygous 
mice where the VGV isoform accounts for approximately 50%, is 
markedly different from the native situation where the VGV isoform 
represents less than 5%. It is possible that some aberrant regulatory 
mechanism, which is not engaged under normal circumstances, is 
responsible for the marked increase in 5-HT2C-VGV receptor density 
in the mutant mice. This question can only be deﬁ  nitively answered 
when a method becomes available for isolation and quantiﬁ  cation 
of individual protein isoforms.
Although our pharmacological studies in brains of mice express-
ing the VGV isoform document reduced G-protein coupling capac-
ity, the marked increase in 5-HT2C receptor site density may mitigate 
this diminished cellular signal in the intact animal. To investigate 
the functional consequences in vivo of these opposing effects, we 
employed a behavioral assay of 5-HT2C receptor activation. 5-HT2C 
receptor agonists, such as MK212, have long been known to induce 
hypolocomotion (Fone et al., 1998; Gleason and Shannon, 1998; 
Gleason et al., 2001; Stiedl et al., 2007), although there is debate 
about their speciﬁ  city. Recent studies in 5-HT2C receptor knock-
out mice (Fletcher et al., 2009), showing that MK212-induced 
hypolocomotion is eliminated, suggest that, in mice, this behavior 
is a valid measure of in vivo 5-HT2C receptor activation. We found 
that MK212 elicits a dose-dependent decrease in locomotor activ-
ity in both WT and VGV/Y mice, but the sensitivity to MK212 is 
dramatically increased in VGV/Y mice. This observation conﬁ  rms 
the work of Kawahara et al. (2008), and importantly shows that the 
marked behavioral sensitization is reproduced on another back-
ground strain. These data suggest that the large increase in receptor 
density overcomes the reduced G-protein coupling of the VGV 
receptor. The ﬁ  nding that 5-HT2C antagonists increase locomotor 
activity in VGV/Y mice (Kawahara et al., 2008; data not shown) 
agrees with this interpretation. Given emerging evidence suggesting 
that the 5-HT2C receptor attenuates DA release and 5-HT2C receptor 
antagonists augment the action of dopamine releasing agents such 
as cocaine (Filip and Cunningham, 2003; De Deurwaerdere et al., 
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